For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed the day trading at $21.24 down -0.47% from the previous closing price of $21.34. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 2.04 million shares were traded. ACAD stock price reached its highest trading level at $21.55 during the session, while it also had its lowest trading level at $21.0.
Ratios:
For a better understanding of ACAD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.15. For the most recent quarter (mrq), Quick Ratio is recorded 2.83 and its Current Ratio is at 2.91. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 15 ’25 when Schneyer Mark C. sold 3,498 shares for $23.65 per share. The transaction valued at 82,728 led to the insider holds 43,447 shares of the business.
GAROFALO ELIZABETH A. sold 1,600 shares of ACAD for $41,560 on Sep 02 ’25. The Director now owns 25,382 shares after completing the transaction at $25.98 per share. On Aug 18 ’25, another insider, Schneyer Mark C., who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 22,000 shares for $25.18 each. As a result, the insider received 554,024 and left with 40,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3583447552 and an Enterprise Value of 2877745664. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.96, and their Forward P/E ratio for the next fiscal year is 25.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.52 while its Price-to-Book (P/B) ratio in mrq is 4.35. Its current Enterprise Value per Revenue stands at 2.824 whereas that against EBITDA is 27.68.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.75, which has changed by 0.44972825 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $26.65, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is -12.11%, while the 200-Day Moving Average is calculated to be 6.18%.
Shares Statistics:
Over the past 3-months, ACAD traded about 2.03M shares per day on average, while over the past 10 days, ACAD traded about 2783250 shares per day. A total of 168.61M shares are outstanding, with a floating share count of 167.39M. Insiders hold about 0.79% of the company’s shares, while institutions hold 101.09% stake in the company. Shares short for ACAD as of 1757894400 were 7984950 with a Short Ratio of 3.94, compared to 1755216000 on 9983774. Therefore, it implies a Short% of Shares Outstanding of 7984950 and a Short% of Float of 7.4200004.
Earnings Estimates
Current recommendations for the stock of the company come from 14.0 analysts. The consensus estimate for the next quarter is $0.13, with high estimates of $0.27 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.89 and $0.42 for the fiscal current year, implying an average EPS of $0.56. EPS for the following year is $0.88, with 15.0 analysts recommending between $1.93 and $0.17.
Revenue Estimates
17 analysts predict $276.52M in revenue for. The current quarter. It ranges from a high estimate of $291.06M to a low estimate of $271.8M. As of. The current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $250.4MFor the next quarter, 17 analysts are estimating revenue of $286.69M. There is a high estimate of $306.5M for the next quarter, whereas the lowest estimate is $278.8M.
A total of 19 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.06B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $957.8MBased on 18 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.33B and the low estimate is $1.12B.
